153 related articles for article (PubMed ID: 27585671)
21. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
[TBL] [Abstract][Full Text] [Related]
22. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
23. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes.
Luo Y; Paul SK; Zhou X; Chang C; Chen W; Guo X; Yang J; Ji L; Wang H
J Diabetes Res; 2017; 2017():7602408. PubMed ID: 28168204
[No Abstract] [Full Text] [Related]
24. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
Gastaldelli A; Casolaro A; Pettiti M; Nannipieri M; Ciociaro D; Frascerra S; Buzzigoli E; Baldi S; Mari A; Ferrannini E
Clin Pharmacol Ther; 2007 Feb; 81(2):205-12. PubMed ID: 17259945
[TBL] [Abstract][Full Text] [Related]
25. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
26. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2).
Ramachandran A; Snehalatha C; Mary S; Selvam S; Kumar CK; Seeli AC; Shetty AS
Diabetologia; 2009 Jun; 52(6):1019-26. PubMed ID: 19277602
[TBL] [Abstract][Full Text] [Related]
27. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
Osei K; Gaillard T; Schuster D
Metabolism; 2007 Jan; 56(1):24-9. PubMed ID: 17161222
[TBL] [Abstract][Full Text] [Related]
28. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
Wallace TM; Levy JC; Matthews DR
Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
[TBL] [Abstract][Full Text] [Related]
29. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.
Nakayama T; Komiyama N; Yokoyama M; Namikawa S; Kuroda N; Kobayashi Y; Komuro I
Int J Cardiol; 2010 Jan; 138(2):157-65. PubMed ID: 18817993
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
[TBL] [Abstract][Full Text] [Related]
32. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
[TBL] [Abstract][Full Text] [Related]
33. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Retnakaran R; Qi Y; Harris SB; Hanley AJ; Zinman B
Diabetes Care; 2011 Jul; 34(7):1601-4. PubMed ID: 21709296
[TBL] [Abstract][Full Text] [Related]
34. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
35. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
[TBL] [Abstract][Full Text] [Related]
36. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
[TBL] [Abstract][Full Text] [Related]
37. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
38. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
[TBL] [Abstract][Full Text] [Related]
39. Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients.
Yu X; Chen P; Wang H; Zhu T
Med Princ Pract; 2013; 22(2):156-60. PubMed ID: 22964975
[TBL] [Abstract][Full Text] [Related]
40. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
